Randomized Trial of Micafungin for the Prevention of Invasive Fungal Infection in High-Risk Liver Transplant Recipients

Randomized Trial of Micafungin for the Prevention of Invasive Fungal Infection in High-Risk Liver Transplant Recipients

In this randomized clinical trial comparing micafungin 100 mg with standard-care antifungal prophylaxis (fluconazole, liposomal amphotericin B, or caspofungin) in high-risk liver transplant patients, micafungin 100 mg was noninferior and had a better kidney safety profile.

Bibliographic Details
Main Authors: Saliba, Faouzi, Pascher, Andreas, Cointault, Olivier, Laterre, Pierre-François, Cervera, Carlos, De Waele, Jan J., Cillo, Umberto, Langer, Róbert M., Lugano, Manuela, Göran-Ericzon, Bo, Phillips, Stephen, Tweddle, Lorraine, Karas, Andreas, Brown, Malcolm, Fischer, Lutz, Pratschke, Johann, Decruyenaere, Johan, Moreno, Christophe, Michielsen, Peter, Neuhaus, Peter, Schemmer, Peter, Varo, Evaristo, Montejo, Miguel, Bouza, Emilio, Blanes, Marino, De La Torre, Julián, Fortun, Jesus, Rostaing, Lionel, Paugam-Burtz, Catherine, Eyraud, Daniel, Shah, Tahir, Heaton, Nigel, McCormick, Aiden, Salizzoni, Mauro, De Gasperi, Andrea, Tomé, Luís, Daniel, Jorge, Popescu, Irinel, Moysyuk, Yan G., Chzhao, Alexey V., Zagaynov, Vladimir E., Ericzon, Bo-Göran
Format: Online
Language:English
Published: Oxford University Press 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357288/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357288/

Similar Items